Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
复制标题
DOI：
10.1016/j.diabres.2008.03.018
复制
发表时间：
2008-08-01
影响因子：
5.1
通讯作者：
Kaku, K.
中科院分区：
文献类型：
--
作者：
Seino, Y.;Rasmussen, M. F.;Kaku, K.
目的：在日本2型糖尿病受试者中评价每日一次人GLP-1类似物利拉鲁肽的剂量效应疗效和安全性。患者（226例，接受含/不含OAD饮食治疗，平均HbA（1c）8.30%，平均BMI 23.9 kg/m2）在OAD停药和洗脱后随机接受利拉鲁肽0.1、0.3、0.6或0.9 mg每日一次，结果：与安慰剂相比，利拉鲁肽剂量水平降低HbA（1c）（分别降低0.79%、1.22%、1.64%和1.85%;线性对比p < 0.0001）。利拉鲁肽0.9 mg/天导致75%的患者达到HbA（1c）
Aims: To evaluate dose-response efficacy and safety of once-daily human GLP-1 analog liraglutide in Japanese subjects with type 2 diabetes.Methods: Patients (226, treated with diet with/without OADs, mean HbA(1c) 8.30%, mean BMI 23.9 kg/m(2)) were randomized after OAD discontinuation and washout to receive liraglutide 0.1, 0.3, 0.6 or 0.9 mg once daily, or placebo in double-blind, parallel-group design for 14 weeks.Results: Liraglutide dose levels reduced HbA(1c) versus placebo (by 0.79%, 1.22%, 1.64% and 1.85%, respectively; p < 0.0001 for linear contrast). Liraglutide 0.9 mg/day resulted in 75% of patients achieving HbA(1c)